ASH 2022 | Outcomes of patients with CLL-associated autoimmune cytopenias treated with different therapies

This is actually a very exciting study that was really led by one of our medical students, Isaac Esplin. And this is a retrospective cohort study serving our institutional experience with autoimmune cytopenias in patients with CLL. So we looked at both autoimmune hemolytic anemia and ITP. And we looked at response at both six weeks and six months as well as therapies they’d received.

The main goal of this was not only to try to see overall response in terms of how many people had a response at both six weeks, and then at six months, but also look at number of therapies received and if there were any types of treatments, like rituximab given earlier that might result in a more favorable response at those time points. We did see that the majority of patients did eventually respond. And actually, the overall survival for both CLL-associated AIHA and ITP was very good. But surprisingly, our analysis of therapies did not identify one that really resulted in better responses or decreased risk of subsequent episodes compared to others. So I look forward to looking at the data a little bit farther, so we can really delve into this large cohort of patients with CLL-associated AIC.